The identification of T cell epitopes is crucial for the understanding of the host immune response during infection. While much is known about the MHC class I-restricted response following influenza virus infection of C57BL/6 mice, with over 16 CD8 epitopes identified to date, less is known about the MHC class II-restricted response. Currently, only a few I-A b -restricted T helper epitopes have been identified. Therefore, several important questions remain about how many class II epitopes exist in this system and whether these epitopes are evenly distributed within the most abundant viral proteins. In order to address these questions, we analyzed the repertoire of epitopes that drive the CD4 + T cell response to influenza virus infection in C57BL/6 (H-2 b ) mice. Using a panel of overlapping peptides from each of the viral proteins we show that approximately 20-30 epitopes drive the CD4 T cell response and that the majority of these peptides are derived from the NP and HA proteins. We were also able to demonstrate that vaccination with one of the newly identified epitopes, HA 211-225 /A b , resulted in increased epitope-specific T cell numbers and a significant reduction in viral titers following influenza virus challenge.
Introduction
The T cell response to influenza virus infection is directed at processed viral peptides that are presented on the surface of APCs in the context of MHC class I and class II molecules [1, 2] . While substantial progress has been made in understanding the mechanisms involved in the acquisition and processing of viral proteins into peptides, less is known about the number of epitopes involved in a T cell response. The best understood system is the class I-restricted CD8 + T cell response to influenza virus infection in inbred mice. For example, 16 H-2K b and H-2D b -restricted epitopes have been identified in C57BL/6 mice following influenza virus infection and these epitopes have provided insight into the breadth of the T cell response and patterns of immunodominance [3] [4] [5] [6] [7] [8] . In addition, these epitopes have provided a basis for mechanistic and vaccine studies, and reagent devel-opment, including MHC-peptide tetramers. In stark contrast, much less is known about the class II-restricted CD4 + T cell response in C57BL/6 mice, with only two putative I-A b -restricted epitopes identified in the influenza x31 virus [9, 10] . The comparative lack of information on the CD4 + T cell response partially reflects the difficulties in identifying potential class II-restricted epitopes. In general, peptide binding to MHC class II molecules is less stringent than for peptide binding to MHC class I molecules. Thus, it has been correspondingly difficult to develop algorithms to predict potential class IIrestricted epitopes [11, 12] . One of the more recently developed algorithms, RANKPEP, allows for the input of protein sequences and then determines the rank and percentile optimal binding of the predicted class II epitope [11, 12] . However, it is still unknown whether this algorithm can accurately predict class II epitopes in most proteins.
Because of the lack of detailed information on class IIrestricted epitopes in the murine influenza virus model, many questions remain unanswered regarding the specificity and diversity of the CD4 + T cell response. For example, it is believed that the CD4 + T cell response is much more diverse than the CD8 + T cell response in terms of the number of epitopes recognized; however, there is no direct evidence for this supposition. In addition, it is not known whether CD4 + T cell epitopes are evenly distributed within specific viral proteins, although there is some evidence that they may be enriched in regions of proteins that are recognized by antibodies [13, 14] . There is also little information on the capacity of CD4 + T cell epitopes to mediate effective antiviral immunity in the context of peptide-based vaccines. Clearly, there is a need to develop a better understanding of the numbers and distribution of MHC class II-restricted epitopes in the influenza virus.
Here we analyzed the breadth of the CD4 + T cell response to influenza virus in C57BL/6 mice using a panel of peptides derived from all the major proteins of the x31 strain of influenza virus and compared the epitopes identified by functional studies with those predicted by the RANKPEP algorithm. We demonstrate that CD4 + T cell epitopes are unevenly distributed in a limited number of proteins and estimate the total number of distinct epitopes to be in the range of 20-30, most of which were not predicted by the RANKPEP program. Two of these epitopes appear to be immunodominant inasmuch as they drive a major fraction of the CD4 + T cell response to acute influenza virus infection. Additionally, we found that vaccination with one of these CD4 epitopes resulted in an enhanced CD4 + T cell response and a significant decrease in viral loads following a subsequent influenza virus challenge.
Materials and methods

Generation of influenza peptides and epitope prediction
Amino acid sequences were obtained from PubMed for the proteins of the A/HK-x31 (x31, H3N2) and A/ PR8/34 (PR8, H1N1) strains of the influenza virus. Lyophilized non-amidated peptides, 15 mers overlapping by 10, were generated and purchased from New England Peptide (Gardner, MA) and solubilized with a 50:50 acetonitrile/H 2 O solution. To avoid multiple freeze/thaw cycles, the peptides were then diluted to a concentration of 0.5 μg/ml with Hank's Balance Salt Solution and aliquoted into round bottom 96 well plates. Potential T cell epitopes (MHC II-I-A b ) were predicted using the matrixbased algorithm RANKPEP [11, 12] .
Viruses, animals, and infections
The reassortant influenza virus strain A/HK-x31 (x31, H3N2 = A/Hong Kong/1/68 × A/Puerto Rico/8/34) was grown, stored and titrated as previously described [15] . Female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice (6-12 weeks) were anesthetized by i.p. injection with 2,2,2 tribromoethanol and infected intranasally with 300 or 600 50% egg infectious doses (EID 50 ) of influenza virus.
Enzyme-linked immunospot assay (ELISpot)
The numbers of IFNγ-secreting cells derived from spleens of infected mice were determined after stimulation with influenza peptides in a standard enzyme-linked immunospot (ELISpot) assay [16] . Briefly, 96 well Multiscreen mixed ester nitrocellulose plates (Millipore, Bedford, MA) were coated overnight at 4 °C with 100 μl well of rat anti-mouse IFNγ (B-D Pharmingen, San Jose, CA) at a concentration of 10 μg/ml. The plates were then washed and blocked before the addition of 10 5 responding cells, irradiated (3000 rad) syngeneic normal spleen cells, 10 μg/ml peptide, and 40 U/ml IL-2. Plates were then incubated 48 h at 37 °C and developed overnight with a biontinylated detection antibody, rat anti-mouse IFNγ (B-D Pharmingen, San Jose, CA). The plates were then incubated with streptavidin-alkaline phosphatase (DakoCytomation, Carpinteria, CA) for 1 h, washed, and incubated with BCIP/NBT alkaline phosphatase substrate (Sigma, St. Louis, MO) for 2 h at room temperature. Visible spots of IFNγ secreting cells were then enumerated using an Olympus SZH stereo zoom microscope system.
Intracellular cytokine staining
Lymphocytes were collected from the spleens or lung airways (broncoalveloar lavage) as previously described [17] . Following collection, the cells were washed and depleted of erythrocytes. Isolated cells (10 6 cells/condition) were cultured at 37 °C for 5 h in the presence of 10 μg of the indicated peptide in 250 μl of complete tumor medium (CTM) containing 10 μg/ml Brefeldin A (BFA; Epicenter Technologies, Madison, WI) and 10 U/ml IL-2 (R&D Systems, Minneapolis, MN) [18] . After culture, the cells were blocked with monoclonal antibodies to FcRIII/ II receptor (B-D Pharmingen, San Jose, CA) and stained with anti-CD4 conjugated to FITC anti-CD8 conjugated to PerCP, and anti-CD44 conjugated to allophycocyanin antibodies (B-D Pharmingen, San Jose, CA) in PBS/BFA. The cells were then fixed in 2% formaldehyde, permeabilized with buffer containing 0.5% saponin, and stained with anti-IFNγ conjugated to PE (B-D Pharmingen, San Jose, CA) monoclonal antibody. 200,000 events were collected on a Becton Dickinson FACSCalibur flow cytometer. Data was analyzed using FlowJo (TreeStar) software.
Generation of LacZ-inducible T cell hybridomas
Splenocytes were harvested from C57BL/6 mice 28 days after intranasal challenge with A/HKx31. 30 × 10 6 immune splenocytes were cultured with 30 × 10 6 irra-diated (3000 rad) peptide pulsed (2 μg/ml specific peptide) syngeneic splenocytes for 5 days. Blast cells were enriched by Ficoll and then fused with BWZ.36 cells [19, 20] . The resulting clones were tested for specificity using peptide-pulsed L cells transfected with the I-A b MHC genes.
Antigen presentation assays
Antigen presentation assays were performed as previously described [20] [21] [22] [23] [24] . Briefly, hybridomas (1 × 10 5 ) were cultured with virus-infected or peptide-pulsed cells in flat-bottomed microtiter plates. The plates were incubated overnight, washed with PBS and fixed with β-galactosidase fixative (2% formaldehyde/0.2% glutaraldehyde). Cells were washed again with PBS followed by the addition of 50 μl of a 1 mg/ml X-gal solution (5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 2 mM magnesium chloride). After 4 h, the hybridomas were examined under a light microscope for the presence of blue cells.
Bone marrow derived dendritic cells and vaccination
Bone marrow was flushed from the femurs of C57BL/ 6 mice, depleted of erythrocytes, and 2 × 10 6 mononuclear cells were placed into a bacteriological Petri dish with media supplemented with 20 ng/ml recombinant murine granulocyte/macrophage colony-stimulating factor (rmGM-CSF; Peprotech, Rocky Hill, NJ) and incubated at 37 °C with 10% CO 2 [25] . On day 3, an additional 10 ml of CTM containing 20 ng/ml rmGM-CSF was added. On day 6, half of the cells were removed, centrifuged, and added back to the same plate in 10 ml of fresh media containing 20 ng/ml rmGM-CSF. On day 8 the cells were removed, centrifuged, and 2 × 10 6 cells were placed into new bacteriological Petri dishes in 10 ml of media supplemented with 20 ng/ml rmGM-CSF. On day 10 of the culture, the cells were resuspended at 5 × 10 6 /ml and incubated at 37 °C for 3 h with peptide at a concentration of 50 μg/ml [18] . Following peptide pulsing, the dendritic cells were washed and 100 μl of cells in PBS were injected i.v. into mice at a final concentration of 1 × 10 6 cells per mouse [18] . Three weeks post dendritic cell vaccination, the mice were injected subcutaneously with 100 μg of peptide emulsified in incomplete Freud's adjuvant [26] .
Viral titers
Homogenized lungs were serially diluted and injected into three 10 day old embryonated hen eggs per sample. After incubation at 35 °C for 48 h, allantoic fluid from each egg was sampled and assayed for hemagglutinating activity using chicken red blood cells as previously described [27] . Samples were scored as positive when two of the three eggs contained hemagglutinating activity [27] .
Results
Primary screen for T cell epitopes within influenza virus proteins
To identify MHC class II-restricted epitopes from influenza virus, we synthesized a panel of 15-mer peptides (overlapping by 10 amino acids) from each of the published x31 influenza virus protein sequences and from the PR8 influenza virus hemagglutinin (HA) and neuraminidase (NA) protein sequences (Table 1) . Altogether, a total of 1085 peptides were synthesized and are listed in Supplemental Tables 1 and 2. These peptides were then used to screen splenocytes from mice that had recovered from a prior intranasal x31 infection (21 days post-infection) in two independent ELISpot assays. As shown in Figure 1 and Figure 2 , many of the peptides elicited ELISpot responses that were above three standard deviations of the background (i.e. more than 10 spots). The majority of these positive responses were elicited by peptides derived from the HA, nucleoprotein (NP), acidic polymerase (PA) and basic polymerase (PB1 and PB2) proteins of x31 ( Figure 1 ). Relatively few positive responses were elicited by peptides derived from the NA, nonstructural (NS1 and NS2) and matrix (M1 and M2) proteins of x31 ( Figure 2 ). In addition, peptides from the HA and NA proteins of PR8 virus did not elicit positive responses from the x31primed spleen cells ( Figure 1 and Figure 2 ), consistent with the relatively limited sequence homology between these proteins in the x31 and PR8 viruses. As expected, the screen clearly identified the regions of NP that had previously been reported by Gao et al. to contain an I-A b epitope (NP 261-290 and NP 411-435 ) [9, 10] . These regions are indicated by the yellow bars in Figure 1 .
Since the splenocytes used for the ELISpot assay included both CD4 and CD8 cells, the data did not discriminate between MHC class II-and class I-restricted responses. Although class I peptides are typically shorter than the 15-mer peptides synthesized for this study, it is known that 15 mer peptides can be presented to CD8 + T cells under these conditions, albeit with reduced efficiency [28, 29] . Therefore, we scanned the ELISpot data for known immunodominant class I epitopes, NP 366-374 , PA 224-233 , and PB1 703-711 . Responses to all three of these epitopes were detected in the ELISpot screen as indicated by the blue bars in Figure 1 . Taken together, these results suggested that our screen likely identified a combination of class I and class II-restricted epitopes.
Contributions of selected epitopes to T cell responses to primary x31 infection
Since we had identified a reasonable number of epitopes that were not known class I-restricted epitopes, we assumed that most of these epitopes were likely to be class II-restricted CD4 T cell epitopes. To determine whether the RANKPEP algorithm could be used to accurately predict the CD4 epitopes identified in our screen, we screened the x31 viral proteins using the RANKPEP algorithm and, using this program, identified a large number of peptides that were predicted to bind I-A b with a range of efficiencies ( Table 2 and data not shown). However, there was only a partial correlation with the ELISpot data ( Table 2 and data not shown), and many epitopes identified in our functional screen were not identified by the RANKPEP program. Interestingly, the algorithm did predict two potentially strong I-A b binding peptides in the NP 261-290 region defined by Gao et al.; 266 LRGSVAHKS 274 and 277 PACVYGPAVA 286 ( Table 2 ), suggesting that a subset of CD4 epitopes can be identified by this method.
Next, to further investigate the specificity of the T cell response to influenza virus infection, we selected 36 peptides for additional characterization ( Table 2 ). These peptides were selected on the basis that (i) they gave greater than 20 ELISpots in two independent screening assays, and/or (ii) they had a RANKPEP score of greater than 32% optimal (this score was selected as it typically identified the top 10% of predicted I-A b binders in any given protein). We also excluded all peptides that contained known class I epitopes and peptides from the regions previously described by Gao et al. [9, 10] . Table 2 shows the list of 36 peptides (plus the Gao et al. peptides) with the corresponding ELISpot results and RANKPEP scores. Even though these peptides were the top candidates for I-A b -restricted epitopes, there was not a direct correlation between the number of ELISpots elicited by these peptides and their respective RANKPEP scores. For example, NP 311-325 elicited strong ELISpot responses but was only 20% optimal by RANKPEP whereas PA 456-470 elicited weak ELISpot responses but was 38% optimal by RANK-PEP (Table 2 ). Of 36 peptides in Table 2 that were positive by ELISpot, only six received a RANKPEP score of greater than 32%.
We next analyzed the capacity of the 36 selected peptides to stimulate IFNγ production during an acute response to influenza virus infection using an intracellular cytokine assay. This approach allowed us to: (i) confirm specific epitopes in an independent assay; (ii) identify those epitopes that made significant contributions to the acute response to infection and (iii) specifically distinguish class I and class II responses. C57BL/6 mice were intranasally infected with influenza virus and 10 days later cells were recovered from the lung airways. These cells were then assessed for their ability to produce IFNγ in an intracellular cytokine assay following stimulation with each of the 36 peptides (the known class I epitopes, NP 366-374 and PA 224-233 , and the Gao peptide, NP 276-290 , were included as controls). As shown in Figure 3 almost all of the peptides tested induced IFNγ in these effector T cells and over half of the peptides induced IFNγ production in greater than 1% of either the CD4 or CD8 T cell populations. Ten of these peptides stimulated CD4 T cells, eight stimulated CD8 T cells, while two peptides stimulated both CD4 and CD8 T cells to produce IFNγ. Representative data from six of these peptides are shown on the right hand panel of Figure 3 .
T cells specific for the HA 211-225 and NP 311-325 epitopes make substantial contributions to the primary CD4 T cell response to influenza
We next took the two peptides that elicited the strongest IFNγ production in the intracellular cytokine staining assay (HA 211-225 and NP 311-325 ) and re-synthesized them as purified peptides to confirm that they corresponded to bona fide epitopes. Intracellular cytokine staining analysis of these re-synthesized peptides confirmed that they were both class II-restricted epitopes and also demonstrated that the NP 311-325 peptide did not stimulate CD8 T cells (data not shown). It is unclear why the crude NP 311-325 peptide gave an initial response as a mixed CD4 and CD8 epitope. However, we noted that the peptide was originally synthesized in a well adjacent to the known NP 366-374 /D b epitope and we now speculate that there may have been some cross contamination either during the production or subsequent handling of the peptides. We next analyzed the kinetics of the primary T cell response to the purified HA 211-225 and NP 311-325 epitopes. As shown in Figure 4A , both epitopes stimulated strong CD4 + T cell responses that can be first detected on day 8 post infection in the lung airways. The frequency of HA 211-225 and NP 311-325 specific cells peaked at 10% and 11%, respectively, of the total CD4 cells. Since 67% of the total CD4 T cells in the lung airways rapidly respond to activation with PMA and ionomycin treatment, we conclude that approximately 31% of the total influenza-specific CD4 T cells in the lung airways are specific for the HA 211-225 and NP 311-325 epitopes ( Figure 4B ). Together, these data confirm that HA 211-225 and NP 311-325 are bona fide class II-restricted epitopes and further demonstrate that they are relatively dominant epitopes in the class II-restricted CD4 + T cell response following influenza virus infection of C57BL/6 mice. 
The HA 211-225 epitope is presented in the lungs and local draining lymph nodes during influenza virus infection
To further investigate the characteristics of the HA 211-225 /A b epitope, we generated a panel of T cell hybridomas. Spleen cells from mice that had recovered from a prior x31 infection were stimulated in vitro with the HA 211-225 peptide and subsequently fused to a lacZ expressing variant of BW5147 [19] . The resulting hybridomas were screened for reactivity to the HA 211-225 peptide and one hybridoma, H-#-SM101.3, was selected for further study. This hybridoma was re-cloned and was shown to specifically re-spond to the HA 211-225 peptide pulsed L cells transfected with the I-A b molecule ( Figure 5A ). The hybridoma also responded to syngeneic spleen cells infected with various doses of x31 influenza virus ( Figure 5B ). We next used the H-#-SM101.3 hybridoma to investigate the presentation of the HA 211-225 /A b epitope ex vivo by antigen presenting cells isolated from infected mice. Cells were isolated from the lung airways, lung parenchyma, MLN, and spleen on days 4 ( Figure 5C ) and 6 ( Figure 5D ) post influenza virus infection. Increasing numbers of cells from infected mice were then cultured with the H-#-SM101.3 hybrid and the number of hybridoma cells responding to the HA 211-225 peptide was determined one day later. As shown in Figure 5 panels C and D, cells presenting the HA 211-225 /A b epitope were clearly detected at days 4 and 6 in the lung airways, lung parenchyma, and MLN, but not in the spleen. Extrapolation of the titration curves in Figure 4 indicates that at least 1 in 1000 cells in the lungs and MLN are presenting the HA 211-225 /A b epitope at both time points. Together, these data indicate that the HA 211-225 /A b epitope is widely expressed during the course of an influenza virus infection.
Partial control of viral infection in HA 211-225 vaccinated mice
To investigate the capacity of T cells specific for the HA 211-225 /A b epitope to mediate antiviral control, we vaccinated mice with dendritic cells that had been pulsed with the HA 211-225 peptide (control mice were left unvaccinated). Three weeks post vaccination, the mice were boosted with peptide emulsified in incomplete Freud's adjuvant and then infected with x31 influenza virus 2 weeks later. The absolute numbers of antigen-specific T cells in the secondary lymphoid organs and the viral loads in the lungs were determined on various days postinfection. Vaccination with dendritic cells pulsed with the HA 211-225 peptide did not significantly alter the number of CD8 + T cells migrating to the lungs following infection (data not shown). However, HA 211-225 /A b -specific cells were detected earlier in the lymphoid organs of vaccinated mice as compared to unvaccinated mice (day 6 versus day 8) ( Figure 6A ). In addition, substantially greater numbers of antigen-specific T cells were detected in vaccinated mice on day 8 post-infection ( Figure 6A ). Analysis of viral loads indicated that there was a significant reduction in viral titers on days 4 and 6 in the vaccinated mice ( Figure 6B ). However, viral clearance was not accelerated, with both vaccinated and unvaccinated mice clearing virus on day 12 ( Figure 6B ). Together these data indicate that vaccination with the HA 211-225 peptide resulted in a significantly enhanced T cell response to viral challenge and a corresponding decrease viral titers in the lungs. However, it did not result in the accelerated clearance of virus from the lungs.
Discussion
A major limitation in our understanding of the CD4 + T cell response to influenza virus infection has been the lack of information on the numbers, source proteins, and relative contributions of class II epitopes that drive the response. To begin to address this problem, we undertook a peptide screen of all the major influenza virus proteins to identify specific epitopes in C57BL/6 mice. This approach identified a large number of T cell epitopes that were derived predominantly from a relatively limited number of proteins. We had initially speculated that the number of epitopes would reflect the length of the protein and its relative abundance in infected cells. Consistent with this, the nucleoprotein and hemagglutinin proteins contained large numbers of epitopes. However, the neuraminidase protein, which is also relatively abundant, did not contain any I-A b -restricted epitopes at all and the acidic polymerase protein, which has a relatively low abundance, appeared to contain multiple epitopes. It should be noted that although no epitopes were detected in the NA protein, this did not appear to reflect a general feature of this protein as multiple epitopes were identified in x31 NA protein in a parallel screen with BALB/c (H-2 d ) mice (data not shown). As expected, there was no cross-reactivity between the HA and NA proteins derived from x31 and PR8 viruses in C57BL/6 mice. This is consistent with reports that these proteins do not elicit cross-reactive antibodies or T cell responses [30, 31] . An important question raised by these studies is what is the absolute number of class II-restricted epitopes involved in the response to infection? Any analysis of the ELISpot data must take into account that: (i) a single epitope can reside on up to three neighboring peptides; (ii) there is potential inclusion of class I-restricted epitopes and (iii) the data include some false positives. The issue of adjacent peptides and known class I epitopes is easily addressed, and taking these issues into account, we estimate that there are approximately 60 putative epitopes in H-2 b mice (approximately 10 each in HA and PB2 and 20 each in NP and PA). The issue of false positives is more difficult to address. However, we can estimate the frequency of real class II epitopes among positive responses based on the analysis of a selected set of peptides in Figure 3 . In this case, we analyzed 36 peptides that corresponded to 21 putative epitopes (taking into account overlapping peptides and excluding peptides that were only positive in the RANKPEP analysis). Ten of them (48%) appeared to be real class II-restricted epitopes that elicited a significant T cell response in an independent intracellular cytokine assay (greater than 1% of CD4 + T cells in the lung airways during an acute response to infection). Thus, we speculate that about 48% of the 60 putative epitopes (about 29 epitopes) identified in the entire screen are likely to be real epitopes. This is in the same range as the number of class I-restricted epitopes that have been identified in this MHC haplotype (16 K b and D b -restricted epitopes) [8, 32] . Moreover, two of the epitopes, HA 211-225 / A b and NP 311-325 /A b , were shown dominate the CD4 + T cell response to infection, accounting for 31% of the CD4 + T cells present in the lung airways at the peak of the response. This is very similar to the pattern of immunodominance in the CD8 + T cell response where a limited number of epitopes dominate the entire response [8, 32] . However, it should be noted that C57BL/6 mice only express a single MHC class II molecule (I-A b ) due to the deletion of the I-Eα gene. Thus, our estimate of the breadth of the CD4 + T cell repertoire in C57BL/6 mice may underestimate the breadth of the repertoire in mice that express multiple MHC class II molecules. Further estimation of the repertoire will come from more detailed follow up analysis of the many putative epitopes identified in this study and a study of responses in mice expressing different MHC haplotypes.
In addition to analyzing T cell responses using an ELISpot assay, we also analyzed the proteins using the RANKPEP algorithm. There was generally only a modest correlation between the two approaches in terms of their ability to identify epitopes ( Table 2 ). For example, the HA 211-225 /A b epitope, which was found to contribute substantially to the CD4 + T cell response, was predicted by RANKPEP to be an immunodominant epitope with a 33.6% optimal binding score and a rank of 3. However, another epitope, which also contributed to the CD4 + T cell response (NP 311-325 /A b ), was not predicted as an immunodominant epitope by RANKPEP with only a 20% optimal binding score and a rank of 14. In contrast, the PA 456-470 peptide elicited weak ELISpot responses but was predicted by RANKPEP to be an optimal binder (38% optimal binding and number 1 rank). Therefore, while the RANKPEP algorithms can be useful in predicting immunodominant epitopes, this methodology can result in both "false positives" (such as PA 456-470 ) and "false negatives" (such as NP 311-325 ).
A critical question regarding the inflammatory CD4 + T cell response has been its capacity to mediate protective immunity. Several studies have indicated that CD4 + T cells are generally not required for protection [33, 34] . However, evidence from a parainfluenza virus system suggests that CD4 + T cells can mediate substantial viral control against secondary challenge [16, 26] and studies using B cell deficient mice have suggested that CD4 T cells play an important role in enhancing protective antibody responses [35] . To address these issues in the influenza virus system, we vaccinated mice with the HA 211-225 peptide and demonstrated that this resulted in significant reductions in viral titers following a subsequent viral challenge. Interestingly, although the numbers of antigenspecific CD4 + T cells was significantly enhanced in the vaccinated mice and persisted through day 12, this did not result in accelerated viral clearance. It is possible that this may reflect a general feature of inflammatory CD4 + T cell responses to influenza virus or the need for antibodies to mediate late viral clearance. However, we have found that transgenic CD4 + effector T cells are able to mediate viral clearance and protection in an adoptive transfer model, suggesting that the effect may be epitope-dependent and reflect differences in effector functions, such as levels of TNFα secretion [36] . In this regard, we have shown that different MHC class I-restricted influenza virus epitopes differ in their capacity to elicit protective immune responses. We are currently addressing these differences experimentally.
In summary, the data presented here indicate that the numbers of influenza virus MHC class II and class I-restricted epitopes in C57BL/6 mice are not significantly different and the T cell response to these epitopes tend to be dominated by only a limited number of epitopes. The data presented here will also provide a basis for further detailed studies of CD4 + T cell responses to influenza virus. 
Appendix B. Supplementary data
Supplemental a Number of Elispots from 10 5 spleen cells, determined in two independent experiments. Peptides were screened on mice that had recovered from an x31 infection. The regions containing the known Class I and Class II epitopes are indicated by shading and the peptides investigated further are in bold.
